<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019214</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065234</org_study_id>
    <secondary_id>NCI-97-C-0046</secondary_id>
    <secondary_id>NCI-97-C-0019</secondary_id>
    <secondary_id>NCI-T96-0046N</secondary_id>
    <nct_id>NCT00019214</nct_id>
    <nct_alias>NCT00001558</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase I/II Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From The Melanoma Associated Antigens MART-1 and gp 100</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from white blood cells treated with antigens may make the body build&#xD;
      an immune response to kill melanoma cells. Interleukin-2 may stimulate a person's white blood&#xD;
      cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may kill more&#xD;
      melanoma cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and how well giving vaccine&#xD;
      therapy and interleukin-2 works compared to vaccine therapy alone in treating patients with&#xD;
      metastatic melanoma that has not responded to previous therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the toxicity, immunologic reactivity, and possible therapeutic efficacy of&#xD;
           immunization with dendritic cells presenting the MART-1 and gp100 melanoma antigens with&#xD;
           or without interleukin-2 in patients with metastatic melanoma.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of dendritic cells pulsed with MART-1 and gp100&#xD;
      antigens.&#xD;
&#xD;
      Patients receive vaccinations with dendritic cells pulsed with MART-1 and gp100 antigens,&#xD;
      either intralymphatically every 4 weeks for 2 doses, or IV every 3 weeks for 4 doses. Some&#xD;
      patients also receive interleukin-2 subcutaneously or IV, over 3-5 days, beginning 24 hours&#xD;
      after immunization.&#xD;
&#xD;
      Cohorts of 2-9 patients receive escalating doses of pulsed dendritic cells IV until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 6 patients experience dose-limiting toxicity. Subsequent cohorts receive cells&#xD;
      with or without interleukin-2. One cohort may expand to 15 patients to determine the accuracy&#xD;
      of immunologic response to the vaccine.&#xD;
&#xD;
      One cohort of 11 patients receives cells intralymphatically without interleukin-2 every 3-4&#xD;
      weeks for 2 courses. Patients with stable disease or who achieve minor, mixed, or partial&#xD;
      response may be retreated.&#xD;
&#xD;
      Patients with stable or responding disease undergo a second course of vaccination. Patients&#xD;
      who completed treatment with vaccine alone and have stable disease, progressive disease,&#xD;
      disease progression after a response, or a partial response with no further improvement may&#xD;
      receive 2 additional courses.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-42 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1997</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma that has failed standard effective&#xD;
             therapy&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST/ALT less than 4 times upper limit of normal&#xD;
&#xD;
          -  Negative hepatitis B surface antigen&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 75 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No major cardiovascular disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No major respiratory disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No major immunological disease&#xD;
&#xD;
          -  No penicillin allergy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior steroid therapy and recovered&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since any other prior therapy and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

